Tech Company Financing Transactions
Gemphire Therapeutics Funding Round
Gemphire Therapeutics, based in Livonia, secured $5.2 million from private investors.
Transaction Overview
Company Name
Announced On
4/27/2016
Transaction Type
Debt
Amount
$5,150,500
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 59 investors participated in the offering as amended. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
17199 N. Laurel Park Dr. 401
Livonia, MI 48152
USA
Livonia, MI 48152
USA
Phone
Website
Email Address
Not Recorded
Overview
Gemphire Therapeutics (NASDAQ: GEMP) mission is to develop novel drugs, such as gemcabene, to treat the large, growing unmet need of dyslipidemia patients who are unable to reach optimal LDL cholesterol or triglyceride levels with statin or other therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Gullans
Chief Financial Officer
Jeff Mathiesen
Chief Medical Officer
Lee Golden
Chief Scientific Officer
Charles Bisgaier
VP - Finance
Amy Rabourn
VP - Manufacturing
Daniela Oniciu
VP - Operations
Liz Masson
VP - R & D
Daniela Oniciu
Browse more venture capital transactions:
Prev: 4/27/2016: Lendix venture capital transaction
Next: 4/27/2016: Netpulse venture capital transaction
Share this article
About Our VC Transactions Data
We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs